Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2002

View Archived Issues

New dosage form of Atrix's Leuprogel licensed in by Sanofi-Synthelabo

InKine submits chemistry supplement for new formulation of Visicol for colon cleansing

SpectRx acquires Sterling Medivations

Unexpected gene regulatory effects by probucol and BO-653

Pharmacia granted rights to foam delivery technology for use with Rogaine

Phase IIb clinical trial of NBI-6024 in diabetes set to commence

Pretarget product candidates in phase Ia clinical trials

MAP acquires European rights for Dopascan Injection for Parkinson's disease imaging

Genzyme Genetics acquires diagnostic cancer rights from Genzyme Molecular Oncology

Uridine derivatives with antibiotic properties reported by Aventis

Chugai researchers design vitamin D3 analogues with antipsoriatic activity

Aventis discloses novel vitronectin receptor antagonists

Kyowa Hakko and Lilly report new potent antitumor compounds

Suntory presents new compounds for the treatment of osteoporosis and other bone diseases

Scientists at Sumitomo identify novel PARP inhibitors

Novel betacin antibiotic described by Versicor

SCAP ligands: a promising new class of hypolipidemic drugs

Peptidomimetic exhibits broad antimicrobial and endotoxin-neutralizing activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...